Amgen Inc. (AMGN) FY2025 YTD Q3 P&L / Income Statement
2025-01-01 to 2025-09-30
Revenue by Product and Service by Geography
2025-01-01 to 2025-09-30
Swipe to see the full flow
Chart details
Amgen Inc. (AMGN) FY2025 YTD Q3 P&L / Income Statement
Income statement for 2025-01-01 through 2025-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 26,885,000,000 US dollars
- Cost of sales
- 9,061,000,000 US dollars
- Gross profit (calculated)
- 17,824,000,000 US dollars
- Operating expenses (calculated)
- 11,464,000,000 US dollars
- Operating income
- 6,360,000,000 US dollars
- Other income (expense), net (calculated)
- 1,102,000,000 US dollars
- Income before income taxes
- 7,462,000,000 US dollars
- Provision for income taxes
- 1,084,000,000 US dollars
- Net income
- 6,378,000,000 US dollars
- Aranesp - UNITED STATES
- 301,000,000 US dollars
- Aranesp - Non-US
- 755,000,000 US dollars
- BLINCYTO - UNITED STATES
- 779,000,000 US dollars
- BLINCYTO - Non-US
- 367,000,000 US dollars
- EVENITY - UNITED STATES
- 1,132,000,000 US dollars
- EVENITY - Non-US
- 369,000,000 US dollars
- ENBREL - UNITED STATES
- 1,675,000,000 US dollars
- ENBREL - Non-US
- 19,000,000 US dollars
- KRYSTEXXA - UNITED STATES
- 905,000,000 US dollars
- KRYSTEXXA - Non-US
- 0 US dollars
- Kyprolis - UNITED STATES
- 673,000,000 US dollars
- Kyprolis - Non-US
- 388,000,000 US dollars
- Nplate - UNITED STATES
- 762,000,000 US dollars
- Nplate - Non-US
- 377,000,000 US dollars
- Otezla - UNITED STATES
- 1,328,000,000 US dollars
- Otezla - Non-US
- 312,000,000 US dollars
- Other products - UNITED STATES
- 3,907,000,000 US dollars
- Other products - Non-US
- 1,283,000,000 US dollars
- Prolia - UNITED STATES
- 2,271,000,000 US dollars
- Prolia - Non-US
- 1,089,000,000 US dollars
- Repatha - UNITED STATES
- 1,146,000,000 US dollars
- Repatha - Non-US
- 1,000,000,000 US dollars
- TEPEZZA - UNITED STATES
- 1,349,000,000 US dollars
- TEPEZZA - Non-US
- 97,000,000 US dollars
- TEZSPIRE - UNITED STATES
- 1,004,000,000 US dollars
- TEZSPIRE - Non-US
- 0 US dollars
- Vectibix - UNITED STATES
- 441,000,000 US dollars
- Vectibix - Non-US
- 415,000,000 US dollars
- XGEVA - UNITED STATES
- 1,064,000,000 US dollars
- XGEVA - Non-US
- 573,000,000 US dollars
- Product sales - UNITED STATES
- 18,737,000,000 US dollars
- Product sales - Non-US
- 7,044,000,000 US dollars
- Selling, general and administrative
- 5,098,000,000 US dollars
- Research and development
- 5,130,000,000 US dollars
- Other
- 1,236,000,000 US dollars
- Revenue before reconciliation (calculated)
- 51,562,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- Components above reported revenue (calculated)
- negative 24,677,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
66.3%
Gross profit / revenue
Operating margin
23.7%
Operating profit / revenue
Cash conversion
131.0%
Operating cash / net income, same period
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!